STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

StrateGIST 1 (IDRX-42-001)

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

D9570C00001

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

1479-0001

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

DESTINY-Lung03

Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors.



<ul class="wp-block-list">
<li>Code NKI: M22CLA</li>



<li>Code firma: MCLA-129-CL01</li>



<li>Code clinicaltrials.gov: NCT04868877</li>
</ul>



Principal Investigator



Dr. G. Ruiter



Drugs 



MET inhibitor



<ul class="wp-block-list">
<li>Cohort A: NSCLC EGFR exon 20 insertion &#8211; Closed</li>



<li>Cohort B: NSCLC cMet exon 14 skipping mutation &#8211; Closed</li>



<li>Cohort C: HNSCC EGFR or cMet driving mutation &#8211; Closed</li>



<li>Cohort F: NSCLC EGFR sensitizing mutations &#8211; Closed</li>



<li>Cohort G: NSCLC osimertinib resistant &#8211; Closed</li>
</ul>



<h2 class="wp-block-heading">Summary</h2>



A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 as monotherapy in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who have progressed after receiving prior therapy for advanced/metastatic disease.



Read more on <a href="https://www.clinicaltrials.gov/study/NCT04868877?term=MCLA-129-CL01&amp;rank=1" data-type="URL" data-id="https://www.clinicaltrials.gov/study/NCT04868877?term=MCLA-129-CL01&amp;rank=1">clinicaltrials.gov</a>



<h3 class="wp-block-heading">Additional comments</h3>



The study is currently closed and it will open again.